All In Biotech

Drug Trial Radar · NCT04066478

Does DHEA IVF Outcomes in Poor Responders?

Does Dehydroepiandrosterone (DHEA) Improve IVF Outcomes in Poor Responders? A Randomised, Double-blind, Placebo Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jun 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

400

Planned (sponsor's estimate)

Start

Oct 8, 2017

Primary completion

Dec 31, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Homerton University Hospital NHS Foundation TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 40 years, up to 42 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a RCT to examine whether DHEA is capable of improving results for poor responders to ovarian stimulation during IVF treatment

Conditions

  • Infertility, Female
  • Poor Response to Ovulation Induction

Interventions

  • DehydroepiandrosteroneDrug

    75mg Dehydroepiandrosterone daily

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical pregnancy ratesTime frame: at 6-8 weeks gestation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Homerton Fertility Centre

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.